Non-Hodgkin lymphoma includes more than 60 distinct cancers that start in the lymph system. Some forms grow slowly and may require no immediate treatment, while others are aggressive and need urgent chemotherapy. Treatment has improved dramatically with targeted therapies and immunotherapies that harness the immune system.
What's actually going on in research
Trials are testing CAR T-cell therapies for more lymphoma types, bispecific antibodies that redirect immune cells to kill cancer, combinations with BTK inhibitors for certain subtypes, and chemotherapy-free regimens. Researchers are studying how to avoid or delay chemotherapy in slow-growing forms and how to cure aggressive lymphomas that return after initial treatment.
CAR T-cell therapy expansion
After initial approval for relapsed lymphoma, CAR T is moving into earlier treatment lines and new subtypes. Trials are testing whether using it sooner leads to better long-term outcomes than waiting until multiple relapses.
Bispecific antibodies
Drugs like glofitamab and epcoritamab link immune T cells directly to lymphoma cells, creating an immediate attack without modifying cells outside the body. These are being tested as alternatives to CAR T and in combination with other treatments.
Chemotherapy-free regimens
Several trials combine targeted drugs like BTK inhibitors with antibodies to avoid traditional chemotherapy entirely. Early results suggest some people with certain lymphoma types can achieve remission without chemo's side effects.
What to know before you search
Eligibility depends on lymphoma subtype, number of prior treatments, how well those treatments worked, overall health, and sometimes specific genetic markers in the cancer.
What types of trials are currently open
- CAR T trials — Testing modified immune cells that attack lymphoma, either as earlier treatment or for new lymphoma subtypes.
- Bispecific antibody trials — Testing drugs that bridge immune cells to lymphoma cells, often given as injections or infusions.
- Targeted therapy trials — Testing pills like BTK inhibitors, PI3K inhibitors, or other drugs that block specific cancer growth signals.
- Combination trials — Testing whether adding new drugs to standard chemotherapy or combining targeted therapies improves outcomes.
- Maintenance trials — Testing whether continuing treatment after remission prevents lymphoma from returning.
Recently added Non-hodgkin Lymphoma trials
Receive proton therapy for chest lymphoma
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
Complete diagnostic tests for lymphoma and Castleman disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD). Overcoming these delays and missed diagnoses requires new approaches to identify lymphoma and MCD.
Find Non-hodgkin Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.